Dr. Tareq Abadl: Low-Titer Group O Whole Blood – Faster, Simpler Resuscitation for Severe Hemorrhage
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Low-Titer Group O Whole Blood (LTOWB)
Faster, simpler resuscitation for severe hemorrhage
What it is
Whole blood from low-titer group O donors, containing RBCs + plasma + platelets in a single unit. Can be issued immediately when patient blood type is unknown—critical in massive bleeding.
Why it matters in trauma care?
- Speed: One product, rapid release → shorter time to first transfusion
- Physiology: Delivers balanced hemostatic resuscitation from the start
Evidence: Observational studies and cohort analyses link earlier LTOWB with lower early mortality and faster resuscitation vs component therapy
- Operational advantages
- Simplified logistics: Replace multiple components with one unit
- Prehospital-ready: Suits EMS, aeromedical, and austere settings
- Inventory efficiency: Streamlined storage and deployment pathways
Safety and evidence status
Reassuring safety signals in civilian use so far
Ongoing RCTs clarifying superiority vs equivalence to components
- Key policy decisions:
Anti-A/B titer thresholds
Leukoreduction strategy
Hemovigilance and outcome tracking
Supply balance to avoid shortages
- Practical implementation notes
- Define indications: Major hemorrhage, prehospital trauma, MTP entry
- Specify product: Titer limits, leukoreduction (if used), storage conditions
- Train teams: Ordering, handling, documentation (ED, OR, EMS)
- Coordinate early: Transfusion committee + regional blood services
Bottom line
LTOWB is a pragmatic, evidence-informed tool that shortens time to transfusion and simplifies hemorrhage resuscitation. It complements—not replaces—component therapy. Adoption should be guided by local epidemiology, supply logistics, and formal policy.
Read more from Dr. Tareq Abadl on Hemostasis Today.
-
Dec 21, 2025, 15:45Mohammadreza Babaei: Anticoagulation versus No Anticoagulation after Intracranial Hemorrhage in Patients with Atrial Fibrillation
-
Dec 21, 2025, 15:19Salvatore Massimo Petrina: High D-Dimer, Negative CT Scan – What’s Your Next Move?
-
Dec 21, 2025, 15:10Oliver Tiebel Invites You to the 4th Dresden Symposium: Hemostasis in AINS 2026
-
Dec 21, 2025, 14:24Strengthening Hematology Field: Livingstone Dogara’s Experience in the ASH Visitor Training Program
-
Dec 21, 2025, 13:54Jessica Herzig on CD86 Expression Correlation with Immune Cell Activation
-
Dec 21, 2025, 13:13Aboubacar Sidiki Doukoure on The WFH Hemophilia Care Training in Guinea
-
Dec 21, 2025, 08:12The Role of Viscoelastic Testing in Assessing Hemostasis: A Challenge to Standard Laboratory Assays?
-
Dec 21, 2025, 07:24Heghine Khachatryan: World Federation of Hemophilia Is Far More Than An Organization
-
Dec 21, 2025, 07:21Arsene Mekinian Announces New Expert Clinic for Refractory Hemato-Immunologic Diseases